Research published in Annals of Internal Medicine (August 1, 2000; 133:165–175, 227–229) suggests that approximately 10% of esophageal adenocarcinoma cases may be associated with long-term use of medications that promote gastric reflux. Esophageal adenocarcinoma has been increasing in incidence over recent decades and occurs more frequently in men than in women.
One well-recognized risk factor for esophageal adenocarcinoma is chronic gastric reflux, a condition in which stomach acid repeatedly flows back into the esophagus. This reflux exposes the esophageal lining to acid irritation, which over time can contribute to tissue changes and increase cancer risk.
Investigators at the Karolinska Institute in Stockholm examined whether medications known to promote reflux might be linked to this cancer. The researchers compared 618 patients with esophageal cancer (including different cancer subtypes) to 820 control subjects without cancer, carefully reviewing prescription drug histories. They focused on five classes of medications known to increase the likelihood of reflux.
The analysis showed that long-term use mattered. Use of these medications for less than five years was not associated with a statistically significant increase in risk. However, individuals who had taken reflux-promoting medications for five years or longer had more than double the risk of developing esophageal adenocarcinoma. In this long-term group, 17.5% developed esophageal adenocarcinoma, compared with 6.6% among those who had not used these medications long-term.
Notably, the increased risk was specific to esophageal adenocarcinoma and was not observed in other types of esophageal cancer, supporting the idea that chronic acid exposure plays a central role in this particular cancer subtype.
These findings do not imply that reflux-promoting medications should never be used, but they do highlight the importance of long-term risk awareness, especially in patients with chronic reflux symptoms. Ongoing monitoring, lifestyle measures that reduce reflux, and periodic reassessment of medication necessity may be prudent in long-term users.
